“The efficient execution by the Nuvalent (NUVL) team to date reflects a shared sense of urgency driven by patient need for additional treatment options – a need that we believe has been clearly demonstrated by the robust enrollment momentum in our ARROS-1 and ALKOVE-1 trials,” said Darlene Noci, chief development officer at Nuvalent. “We believe we are on track to report pivotal data for TKI pre-treated patients from both trials this year and to submit our first NDA by mid-year 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Oncology Prospects: Buy Rating Affirmed by Charles Zhu
- 3 Best Stocks to Buy Now, 1/20/2025, According to Top Analysts
- Opco lists five potential biotech targets into JPMorgan conference
- 3 Best Stocks to Buy Now, 12/31/2024, According to Top Analysts
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls